1921
Volume 103, Issue 1
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

Tafenoquine has been licensed for the single-dose radical cure of in adults; however, it is only recommended in patients with > 70% of normal glucose-6-phosphate dehydrogenase (G6PD) activity. Because this may hinder widespread use, we investigated sex-based treatment strategies in which all adult patients are tested with a qualitative G6PD rapid diagnostic test (RDT). Glucose-6-phosphate dehydrogenase normal males are prescribed tafenoquine in all three strategies, whereas G6PD normal females are prescribed either a low-dose 14-day primaquine regimen (PQ14, total dose 3.5 mg/kg) or a high-dose 7-day primaquine regimen (PQ7, total dose 7 mg/kg), or referred to a healthcare facility for quantitative G6PD testing before prescribing tafenoquine. Patients testing G6PD deficient are prescribed a weekly course of primaquine for 8 weeks. We compared the cost-effectiveness of these three strategies to usual care in four countries using a decision tree model. Usual care in Ethiopia does not include radical cure, whereas Afghanistan, Indonesia, and Vietnam prescribe PQ14 without G6PD screening. The cost per disability-adjusted life-year (DALY) averted was expressed through incremental cost-effectiveness ratios (ICERs). Compared with usual care, the ICERs for a sex-based treatment strategy with PQ7 for females from a healthcare provider perspective were $127 per DALY averted in Vietnam, $466 in Ethiopia, $1,089 in Afghanistan, and $4,443 in Indonesia. The PQ14 and referral options cost more while averting fewer DALYs than PQ7. This study provides an alternative cost-effective mode of rolling out tafenoquine in areas where initial testing with only a G6PD RDT is feasible.

[open-access] This is an open-access article distributed under the terms of the Creative Commons Attribution (CC-BY) License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Loading

Article metrics loading...

The graphs shown below represent data from March 2017
/content/journals/10.4269/ajtmh.19-0943
2020-05-04
2020-09-22
Loading full text...

Full text loading...

/deliver/fulltext/14761645/103/1/tpmd190943.html?itemId=/content/journals/10.4269/ajtmh.19-0943&mimeType=html&fmt=ahah

References

  1. Battle KE et al., 2019. Mapping the global endemicity and clinical burden of Plasmodium vivax, 2000–17: a spatial and temporal modelling study. Lancet 394: 332343.
    [Google Scholar]
  2. Baird JK, Hoffman SL, 2004. Primaquine therapy for malaria. Clin Infect Dis 39: 13361345.
    [Google Scholar]
  3. Thriemer K et al., 2018. Quantifying primaquine effectiveness and improving adherence: a round table discussion of the APMEN Vivax Working Group. Malar J 17: 241.
    [Google Scholar]
  4. Douglas NM, Poespoprodjo JR, Patriani D, Malloy MJ, Kenangalem E, Sugiarto P, Simpson JA, Soenarto Y, Anstey NM, Price RN, 2017. Unsupervised primaquine for the treatment of Plasmodium vivax malaria relapses in southern Papua: a hospital-based cohort study. PLoS Med 14: e1002379.
    [Google Scholar]
  5. Taylor WRJ et al., 2019. Short-course primaquine for the radical cure of Plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority trial. Lancet 394: 929938.
    [Google Scholar]
  6. Chu CS et al., 2018. Comparison of the cumulative efficacy and safety of chloroquine, artesunate, and chloroquine-primaquine in Plasmodium vivax malaria. Clin Infect Dis 67: 15431549.
    [Google Scholar]
  7. Lacerda MVG et al., 2019. Single-dose tafenoquine to prevent relapse of Plasmodium vivax malaria. N Engl J Med 380: 215228.
    [Google Scholar]
  8. Llanos-Cuentas A et al., 2019. Tafenoquine versus primaquine to prevent relapse of Plasmodium vivax malaria. N Engl J Med 380: 229241.
    [Google Scholar]
  9. Howes RE et al., 2012. G6PD deficiency prevalence and estimates of affected populations in malaria endemic countries: a geostatistical model-based map. PLoS Med 9: e1001339.
    [Google Scholar]
  10. World Health Organization, 2016. Testing for G6PD Deficiency for Safe Use of Primaquine in Radical Cure of P. Vivax and P. Ovale Malaria. Geneva, Switzerland: WHO.
    [Google Scholar]
  11. Domingo GJ et al., 2013. G6PD testing in support of treatment and elimination of malaria: recommendations for evaluation of G6PD tests. Malar J 12: 391.
    [Google Scholar]
  12. Ley B et al., 2015. The challenges of introducing routine G6PD testing into radical cure: a workshop report. Malar J 14: 377.
    [Google Scholar]
  13. Chu CS, Bancone G, Nosten F, White NJ, Luzzatto L, 2018. Primaquine-induced haemolysis in females heterozygous for G6PD deficiency. Malar J 17: 101.
    [Google Scholar]
  14. World Health Organization, 2015. Guidelines for the Treatment of Malaria. Geneva, Switzerland: WHO.
    [Google Scholar]
  15. Ley B, Bancone G, von Seidlein L, Thriemer K, Richards JS, Domingo GJ, Price RN, 2017. Methods for the field evaluation of quantitative G6PD diagnostics: a review. Malar J 16: 361.
    [Google Scholar]
  16. Ley B et al., 2019. Performance of the Access Bio/CareStart rapid diagnostic test for the detection of glucose-6-phosphate dehydrogenase deficiency: a systematic review and meta-analysis. PLoS Med 16: e1002992.
    [Google Scholar]
  17. Roy M, Bouma MJ, Ionides EL, Dhiman RC, Pascual M, 2013. The potential elimination of Plasmodium vivax malaria by relapse treatment: insights from a transmission model and surveillance data from NW India. PLoS Negl Trop Dis 7: e1979.
    [Google Scholar]
  18. Devine A, Parmiter M, Chu CS, Bancone G, Nosten F, Price RN, Lubell Y, Yeung S, 2017. Using G6PD tests to enable the safe treatment of Plasmodium vivax infections with primaquine on the Thailand-Myanmar border: a cost-effectiveness analysis. PLoS Negl Trop Dis 11: e0005602.
    [Google Scholar]
  19. Gilder ME et al., 2018. Primaquine pharmacokinetics in lactating women and breastfed infant exposures. Clin Infectious Dis 67: 10001007.
    [Google Scholar]
  20. Pal S et al., 2019. Evaluation of a novel quantitative test for glucose-6-phosphate dehydrogenase deficiency: bringing quantitative testing for glucose-6-phosphate dehydrogenase deficiency closer to the patient. Am J Trop Med Hyg 100: 213221.
    [Google Scholar]
  21. White NJ, 2019. Tafenoquine–a radical improvement? N Engl J Med 380: 285286.
    [Google Scholar]
  22. Abreha T et al., 2017. Comparison of artemether-lumefantrine and chloroquine with and without primaquine for the treatment of Plasmodium vivax infection in Ethiopia: a randomized controlled trial. PLoS Med 14: e1002299.
    [Google Scholar]
  23. Grietens KP et al., 2010. Adherence to 7-day primaquine treatment for the radical cure of P. vivax in the Peruvian Amazon. Am J Trop Med Hyg 82: 10171023.
    [Google Scholar]
  24. Cheoymang A, Ruenweerayut R, Muhamad P, Rungsihirunrat K, Na-Bangchang K, 2015. Patients’ adherence and clinical effectiveness of a 14-day course of primaquine when given with a 3-day chloroquine in patients with Plasmodium vivax at the Thai-Myanmar border. Acta Trop 152: 151156.
    [Google Scholar]
  25. Khantikul N, Butraporn P, Kim HS, Leemingsawat S, Tempongko MA, Suwonkerd W, 2009. Adherence to antimalarial drug therapy among vivax malaria patients in northern Thailand. J Health Popul Nutr 27: 413.
    [Google Scholar]
  26. Devine A et al., 2019. Provider and household costs of Plasmodium vivax malaria episodes: a multicountry comparative analysis of primary trial data. Bull World Health Organ 97: 828836.
    [Google Scholar]
  27. World Health Organization, 2011. WHO-CHOICE Unit Cost Estimates for Service Delivery. Available at: http://www.who.int/choice/cost-effectiveness/inputs/health_service/en/. Accessed February 2, 2016.
    [Google Scholar]
  28. Mulligan J-A, Fox-Rushby JA, Adam T, Johns B, Mills A, 2005. Unit Costs of Health Care Inputs in Low and Middle Income Regions. DCPP Working Paper No. 9.
    [Google Scholar]
  29. Salomon JA et al., 2013. Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. Lancet 380: 21292143.
    [Google Scholar]
  30. World Health Organization, 2016. Life Tables by Country. Available at: http://apps.who.int/gho/data/node.main.LIFECOUNTRY?lang=en. Accessed November 11, 2019.
    [Google Scholar]
  31. The World Bank, 2016. GDP per Capita (Current US$) Available at: http://data.worldbank.org/indicator/NY.GDP.PCAP.CD. Accessed August 27, 2019.
    [Google Scholar]
  32. Ochalek J, Lomas J, Claxton K, 2018. Estimating health opportunity costs in low-income and middle-income countries: a novel approach and evidence from cross-country data. BMJ Global Health 3: e000964.
    [Google Scholar]
  33. Taylor AR et al., 2019. Resolving the cause of recurrent Plasmodium vivax malaria probabilistically. Nat Commun 10: 5595.
    [Google Scholar]
  34. Adekunle AI, Pinkevych M, McGready R, Luxemburger C, White LJ, Nosten F, Cromer D, Davenport MP, 2015. Modeling the dynamics of Plasmodium vivax infection and hypnozoite reactivation in vivo. PLoS Negl Trop Dis 9: e0003595.
    [Google Scholar]
  35. John GK, Douglas NM, von Seidlein L, Nosten F, Baird JK, White NJ, Price RN, 2012. Primaquine radical cure of Plasmodium vivax: a critical review of the literature. Malar J 11: 280.
    [Google Scholar]
  36. Bruxvoort K, Goodman C, Kachur SP, Schellenberg D, 2014. How patients take malaria treatment: a systematic review of the literature on adherence to antimalarial drugs. PLoS One 9: e84555.
    [Google Scholar]
  37. Mbanefo EC et al., 2017. Association of glucose-6-phosphate dehydrogenase deficiency and malaria: a systematic review and meta-analysis. Sci Rep 7: 45963.
    [Google Scholar]
  38. Henriques G et al., 2018. Comparison of glucose-6 phosphate dehydrogenase status by fluorescent spot test and rapid diagnostic test in Lao PDR and Cambodia. Malar J 17: 243.
    [Google Scholar]
  39. Brummaier T, Gilder ME, Gornsawun G, Chu CS, Bancone G, Pimanpanarak M, Chotivanich K, Nosten F, McGready R, 2020. Vivax malaria in pregnancy and lactation: a long way to health equity. Malar J 19: 40.
    [Google Scholar]
  40. Pamba A, Richardson ND, Carter N, Duparc S, Premji Z, Tiono AB, Luzzatto L, 2012. Clinical spectrum and severity of hemolytic anemia in glucose 6-phosphate dehydrogenase-deficient children receiving dapsone. Blood 120: 41234133.
    [Google Scholar]
  41. Rahimi BA, Thakkinstian A, White NJ, Sirivichayakul C, Dondorp AM, Chokejindachai W, 2014. Severe vivax malaria: a systematic review and meta-analysis of clinical studies since 1900. Malar J 13: 481.
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.19-0943
Loading
/content/journals/10.4269/ajtmh.19-0943
Loading

Data & Media loading...

Supplemental appendix, table and figure

  • Received : 18 Dec 2019
  • Accepted : 13 Mar 2020
  • Published online : 04 May 2020
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error